ORHB - InvestorNewsBreaks - HippoFi Inc. (ORHB) Subsidiary Granted Patent for Advanced Cartilage Regeneration and Arthritis Solutions
HippoFi (OTC: ORHB), formerly ORHub Inc., and its wholly owned subsidiary, PUR Biologics, has received a new patent; according to the announcement, the patent covers advanced cartilage regeneration and arthritis solutions that mark a significant advancement in treating the destructive effects of osteoarthritis and cartilage degeneration. The company stated that this addition to its intellectual property portfolio gives PUR Biologics “exclusive rights to innovative methods and compositions that utilize induced Pluripotent Stem Cells (‘iPSCs’) to produce an advanced extracellular matrix (‘ECM’). . .[heralding] a transformative phase in spine and orthopedic treatments.” The announcement noted that the need for effective cartilage regeneration solutions is increasing. The global cartilage repair market is forecast to reach $3.5 billion by 2028, and PUR Biologics has strengthened its position in the market with this new patent. “This patent reflects our ambition in the biotech market, which was estimated at $1.37 trillion in 2022 and is expected to grow at a compound annual growth rate (‘CAGR’) of 13.96% from 2023 to 2030,” said HippoFi CEO and executive chair CJ Wiggins in the press release. “We're excited about the advancement of iPSC-ECM and the promising future to regenerate cartilage, along with our broader vision to remain at the forefront of biotechnological innovations, driving unparalleled value to our investors.”
To view the full press release, visit https://ibn.fm/QClSC
About HippoFi Inc.
HippoFi, formerly ORHub Inc., delivers its cutting-edge healthcare innovations and propriety technologies through an extensive sales channel network, while implementing first-to-market solutions in the multibillion-dollar biotech, fintech and artificial intelligence (“AI”) markets. HippoFi comprises three segments — regenerative therapeutics, digital payments and AI — and utilizes the same customer channels to commercialize solutions, drive revenue and improve patient outcomes. For more information, visit the company’s website at www.HippoFi.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.